Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BIFIDOBACTERIUM SPP: 40 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
40
Total FAERS Reports
5 (12.5%)
Deaths Reported
28
Hospitalizations
40
As Primary/Secondary Suspect
1
Life-Threatening
4
Disabilities

First Report: 20110702 · Latest Report: 20230126

What Are the Most Common BIFIDOBACTERIUM SPP Side Effects?

#1 Most Reported
Constipation
19 reports (47.5%)
#2 Most Reported
Pyrexia
14 reports (35.0%)
#3 Most Reported
Off label use
13 reports (32.5%)

All BIFIDOBACTERIUM SPP Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Constipation 19 47.5% 1 16
Pyrexia 14 35.0% 0 14
Off label use 13 32.5% 0 13
Anaemia 12 30.0% 0 12
Drug ineffective 12 30.0% 0 12
Haematochezia 12 30.0% 0 12
Nausea 12 30.0% 0 12
Oral candidiasis 12 30.0% 0 12
Paraesthesia oral 12 30.0% 0 12
Therapeutic product effect incomplete 12 30.0% 0 12
Weight decreased 12 30.0% 0 12
Abdominal pain 11 27.5% 0 11
Chronic sinusitis 11 27.5% 0 11
Colitis 11 27.5% 0 11
Colitis ulcerative 11 27.5% 0 11
Dyspepsia 11 27.5% 0 11
Erythema 11 27.5% 0 11
Female genital tract fistula 11 27.5% 0 11
Frequent bowel movements 11 27.5% 0 11
Headache 11 27.5% 0 11

Who Reports BIFIDOBACTERIUM SPP Side Effects? Age & Gender Data

Gender: 62.8% female, 37.2% male. Average age: 57.2 years. Most reports from: JP. View detailed demographics →

Is BIFIDOBACTERIUM SPP Getting Safer? Reports by Year

YearReportsDeathsHosp.
2011 1 0 1
2012 3 0 2
2013 2 2 1
2014 2 2 0
2015 2 0 2
2016 9 0 5
2017 1 0 1
2018 7 0 7
2019 1 1 1
2023 1 0 0

View full timeline →

What Is BIFIDOBACTERIUM SPP Used For?

IndicationReports
Product used for unknown indication 21

Official FDA Label for BIFIDOBACTERIUM SPP

Official prescribing information from the FDA-approved drug label.